{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:47:51Z","timestamp":1740178071834,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T00:00:00Z","timestamp":1554768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","award":["ANRS 140"],"award-info":[{"award-number":["ANRS 140"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s41669-019-0130-7","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T09:02:40Z","timestamp":1554800560000},"page":"505-515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-Effectiveness Analysis of Lopinavir\/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM)"],"prefix":"10.1007","volume":"3","author":[{"given":"Osvaldo Ulises","family":"Garay","sequence":"first","affiliation":[]},{"given":"Marie Lib\u00e9r\u00e9e","family":"Nishimwe","sequence":"additional","affiliation":[]},{"given":"Marw\u00e2n-al-Qays","family":"Bousmah","sequence":"additional","affiliation":[]},{"given":"Asmaa","family":"Janah","sequence":"additional","affiliation":[]},{"given":"Pierre-Marie","family":"Girard","sequence":"additional","affiliation":[]},{"given":"Genevi\u00e8ve","family":"Ch\u00eane","sequence":"additional","affiliation":[]},{"given":"Laetitia","family":"Moinot","sequence":"additional","affiliation":[]},{"given":"Luis","family":"Sagaon-Teyssier","sequence":"additional","affiliation":[]},{"given":"Jean-Luc","family":"Meynard","sequence":"additional","affiliation":[]},{"given":"Bruno","family":"Spire","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7567-5200","authenticated-orcid":false,"given":"Sylvie","family":"Boyer","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,4,9]]},"reference":[{"key":"130_CR1","unstructured":"CNS Conseil National du SIDA et des h\u00e9patites virales. Prise en charge m\u00e9dicale des personnes vivant avec le VIH\u2014recommandations du groupe d\u2019experts, Sous la Direction du Professeur Philippe Morlat et sous l\u2019\u00e9gide du CNS et de l\u2019ANRS. Actualisation 2018 du rapport 2013 (Internet). https:\/\/cns.sante.fr\/actualites\/prise-en-charge-du-vih-recommandations-du-groupe-dexperts\/ . Accessed 28 May 2018."},{"key":"130_CR2","first-page":"2014","volume":"314","author":"MJ Friedrich","year":"2015","unstructured":"Friedrich MJ. WHO updates HIV treatment and prevention guideline. JAMA. 2015;314:2014.","journal-title":"JAMA"},{"key":"130_CR3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/ije\/dyr164","volume":"41","author":"C Lewden","year":"2012","unstructured":"Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth JC, et al. All-cause mortality in treated HIV-infected adults with CD4\u2009\u2265\u2009500\/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol. 2012;41:433\u201345.","journal-title":"Int J Epidemiol"},{"key":"130_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1089\/apc.2015.0199","volume":"30","author":"HB Krentz","year":"2016","unstructured":"Krentz HB, Gill MJ. The impact of non-antiretroviral polypharmacy on the continuity of antiretroviral therapy (ART) among HIV patients. AIDS Patient Care STDs. 2016;30:11\u20137.","journal-title":"AIDS Patient Care STDs."},{"key":"130_CR5","first-page":"1060","volume":"64","author":"V Supervie","year":"2014","unstructured":"Supervie V, Ekouevi D. Overview of the HIV epidemics in France and worldwide. Rev Prat. 2014;64:1060\u20136.","journal-title":"Rev Prat."},{"key":"130_CR6","doi-asserted-by":"crossref","unstructured":"Trapero-Bertran M, Oliva-Moreno J. Economic impact of HIV\/AIDS: a systematic review in five European countries. Health Econ Rev (Internet). 2014;4. http:\/\/dx.doi.org\/10.1186\/s13561-014-0015-5 .","DOI":"10.1186\/s13561-014-0015-5"},{"key":"130_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/QAD.0b013e32834dce6e","volume":"26","author":"CE Sloan","year":"2012","unstructured":"Sloan CE, Champenois K, Choisy P, Losina E, Walensky RP, Schackmanj B, et al. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS Lond Engl. 2012;26:45.","journal-title":"AIDS Lond Engl."},{"key":"130_CR8","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1016\/S2352-3018(15)00176-9","volume":"2","author":"NI Paton","year":"2015","unstructured":"Paton NI, St\u00f6hr W, Arenas-Pinto A, Fisher M, Williams I, Johnson M, et al. Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial. Lancet HIV. 2015;2:e417\u201326.","journal-title":"Lancet HIV."},{"key":"130_CR9","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1093\/jac\/dkq327","volume":"65","author":"J-L Meynard","year":"2010","unstructured":"Meynard J-L, Bouteloup V, Landman R, Bonnard P, Baillat V, Cabie A, et al. Lopinavir\/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial. J Antimicrob Chemother. 2010;65:2436\u201344.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"130_CR10","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/hiv.12348","volume":"17","author":"JR Arribas","year":"2015","unstructured":"Arribas J, Girard P-M, Paton N, Winston A, Marcelin A-G, Elbirt D, et al. Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomised trials. HIV Med. 2015;17:358\u201367.","journal-title":"HIV Medicine"},{"key":"130_CR11","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1093\/jac\/dky055","volume":"73","author":"J-L Meynard","year":"2018","unstructured":"Meynard J-L, Moinot L, Landman R, Morand-Joubert L, Besseghir A, Kolta S, et al. Week 96 efficacy of lopinavir\/ritonavir monotherapy in virologically suppressed patients with HIV: a randomised non-inferiority trial (ANRS 140 DREAM). J Antimicrob Chemother. 2018;73:1672\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"130_CR12","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1310\/hct1306-308","volume":"13","author":"A Hermes","year":"2012","unstructured":"Hermes A, Squires K, Fredrick L, Martinez M, Pasley M, Trinh R, et al. Meta-analysis of the safety, tolerability, and efficacy of lopinavir\/ritonavir-containing antiretroviral therapy in HIV-1-infected women. HIV Clin Trials. 2012;13:308\u201323.","journal-title":"HIV Clin Trials."},{"key":"130_CR13","doi-asserted-by":"publisher","first-page":"e23726","DOI":"10.1371\/journal.pone.0023726","volume":"6","author":"A Cahn","year":"2011","unstructured":"Cahn P, Montaner J, Junod P, Patterson P, Krolewiecki A, Andrade-Villanueva J, et al. Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV\/r maintenance therapy in HIV patients on the 1st PI-based regimen. PLoS ONE (Internet). 2011;6:e23726.","journal-title":"PLoS ONE (Internet)"},{"issue":"50","key":"130_CR14","first-page":"474","volume":"2009","author":"J Gathe","year":"1999","unstructured":"Gathe J, da Silva BA, Cohen DE, Loutfy MR, Podzamczer D, Rubio R, et al. A once-daily lopinavir\/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J Acquir Immune Defic Syndr. 1999;2009(50):474\u201381.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"130_CR15","first-page":"247","volume":"37","author":"U Restelli","year":"2014","unstructured":"Restelli U, Croce D, Porazzi E, Scolari F, Bonfanti M, Galli M, et al. Health technology assessment in the HIV setting: the case of monotherapy. New Microbiol. 2014;37:247\u201361.","journal-title":"New Microbiol"},{"key":"130_CR16","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s40273-016-0396-x","volume":"34","author":"L Oddershede","year":"2016","unstructured":"Oddershede L, Walker S, St\u00f6hr W, Dunn DT, Arenas-Pinto A, Paton NI, et al. Cost effectiveness of protease inhibitor monotherapy versus standard triple therapy in the long-term management of HIV patients: analysis using evidence from the PIVOT trial. PharmacoEconomics. 2016;34:795\u2013804.","journal-title":"PharmacoEconomics."},{"key":"130_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2165\/11592220-000000000-00000","volume":"9","author":"B Gazzard","year":"2011","unstructured":"Gazzard B, Hill A, Anceau A. Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices. Appl Health Econ Health Policy. 2011;9:217\u201323.","journal-title":"Appl Health Econ Health Policy."},{"key":"130_CR18","unstructured":"CNS Conseil National du SIDA et des h\u00e9patites virales. Prise en charge m\u00e9dicale des personnes vivant avec le VIH\u2014recommandations du groupe d\u2019experts, Sous la Direction du Professeur Philippe Morlat et sous l\u2019\u00e9gide du CNS et de l\u2019ANRS. Optimisation d\u2019un traitement antir\u00e9troviral en situation de succ\u00e8s virologique (Internet). 2017. https:\/\/cns.sante.fr\/wp-content\/uploads\/2017\/01\/experts-vih_optimisation.pdf ."},{"key":"130_CR19","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015."},{"key":"130_CR20","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (HAS). A methodological guide: choices in methods for economic evaluation (Internet). 2012. https:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2012-10\/choices_in_methods_for_economic_evaluation.pdf ."},{"key":"130_CR21","unstructured":"Minist\u00e8re des Affaires sociales et de la Sant\u00e9. Base de donn\u00e9es publique des m\u00e9dicaments. http:\/\/base-donnees-publique.medicaments.gouv.fr\/ ."},{"key":"130_CR22","unstructured":"S\u00e9curit\u00e9 Sociale l\u2019Assurance Maladie. Statistiques et publications (Internet). 2015. http:\/\/www.ameli.fr\/l-assurance-maladie\/statistiques-et-publications\/index.php ."},{"key":"130_CR23","unstructured":"Caisse nationale de l\u2019assurance maladie. Document de travail \u201c\u202fBiologie m\u00e9dicale nomenclature des actes\u201d, 2014 (Internet). http:\/\/www.codage.ext.cnamts.fr\/codif\/nabm\/ ."},{"key":"130_CR24","doi-asserted-by":"crossref","unstructured":"International Monetary Fund: World Economic Outlook Database. 2016. https:\/\/www.imf.org\/external\/pubs\/ft\/weo\/2016\/01\/weodata\/index.aspx .","DOI":"10.5089\/9781513519333.081"},{"key":"130_CR25","volume-title":"User\u2019s manual for the SF-12v2 health survey","author":"J Ware","year":"2009","unstructured":"Ware J, Kosinski M, Turner-Bowker D, Sundaram M, Gandek B, Maruish M. User\u2019s manual for the SF-12v2 health survey. 2nd ed. New York: U S Qual Inc; 2009.","edition":"2"},{"key":"130_CR26","unstructured":"The University of Sheffield. Measuring and valuing health (Internet). https:\/\/www.sheffield.ac.uk\/scharr\/sections\/heds\/mvh\/index ."},{"key":"130_CR27","doi-asserted-by":"publisher","first-page":"d1548","DOI":"10.1136\/bmj.d1548","volume":"342","author":"S Petrou","year":"2011","unstructured":"Petrou S, Gray A. Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting. BMJ. 2011;342:d1548.","journal-title":"BMJ"},{"key":"130_CR28","volume-title":"Economic evaluation in clinical trials","author":"HA Glick","year":"2014","unstructured":"Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials. 2nd ed. Oxford: Oxford University Press; 2014.","edition":"2"},{"key":"130_CR29","volume-title":"Applied methods of cost-effectiveness analysis in healthcare","author":"AM Gray","year":"2011","unstructured":"Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S. Applied methods of cost-effectiveness analysis in healthcare. Oxford: Oxford University Press; 2011."},{"key":"130_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1590\/S1020-49892002000800017","volume":"12","author":"JD Sachs","year":"2002","unstructured":"Sachs JD. Macroeconomics and health: investing in health for economic development. Rev Panam Salud P\u00fablica. 2002;12:143\u20134.","journal-title":"Rev Panam Salud P\u00fablica."},{"key":"130_CR31","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/1099-1050(200010)9:7<623::AID-HEC539>3.0.CO;2-V","volume":"9","author":"M Lothgren","year":"2000","unstructured":"Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ. 2000;9:623\u201330.","journal-title":"Health Econ"},{"key":"130_CR32","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0167-6296(01)00086-8","volume":"20","author":"WG Manning","year":"2001","unstructured":"Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001;20:461\u201394.","journal-title":"J Health Econ."},{"key":"130_CR33","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: OUP; 2006."},{"key":"130_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1472-6963-6-52","volume":"6","author":"E Fenwick","year":"2006","unstructured":"Fenwick E, Marshall DA, Levy AR, Nichol G. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv Res. 2006;6:52.","journal-title":"BMC Health Serv Res."},{"key":"130_CR35","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/cid\/ciy382","volume":"67","author":"S Lambert-Niclot","year":"2018","unstructured":"Lambert-Niclot S, Grude M, Meynard J-L, Marcelin A-G, Valantin M-A, Flandre P, et al. Ultrasensitive human immunodeficiency virus type 1 viral load as a marker of treatment choice for simplification strategies. Clin Infect Dis. 2018;67:1883\u20139.","journal-title":"Clin Infect Dis"},{"key":"130_CR36","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1097\/QAD.0000000000001467","volume":"31","author":"E Papot","year":"2017","unstructured":"Papot E, Landman R, Louni F, Charpentier C, Peytavin G, Certain A, et al. Budget impact of antiretroviral therapy in a French clinic cohort. AIDS. 2017;31:1271\u20139.","journal-title":"AIDS."},{"key":"130_CR37","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/S0149-2918(00)80088-0","volume":"22","author":"T Delate","year":"2000","unstructured":"Delate T, Coons SJ. The discriminative ability of the 12-Item short form health survey (SF-12) in a sample of persons infected with HIV. Clin Ther. 2000;22:1112\u201320.","journal-title":"Clin Ther"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-019-0130-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s41669-019-0130-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-019-0130-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T19:15:32Z","timestamp":1721157332000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s41669-019-0130-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,9]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["130"],"URL":"https:\/\/doi.org\/10.1007\/s41669-019-0130-7","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"type":"print","value":"2509-4262"},{"type":"electronic","value":"2509-4254"}],"subject":[],"published":{"date-parts":[[2019,4,9]]},"assertion":[{"value":"9 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was sponsored and funded by the French National Institute for Health and Medical Research\u2013France Recherche Nord&Sud Sida-HIV Hepatites (Inserm-ANRS), Paris, France. ANRS 140 DREAM trial was conducted with the support of AbbVie, Bristol-Myers Squibb and Gilead Science.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"BS received fees from Merck Sharp and Dohme, Gilead and Jansen-Cilag for seminars and participation in scientific boards of observational studies. OUG, MLN, MQB, AJ, P-MG, GC, LM, LST, J-LM and SB have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol was approved by the ethics committee \u201cComit\u00e9 de Protection des Personnes Ile de France V, Paris, France\u201d and the French competent health authority (Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et produits de sant\u00e9).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All study participants provided written informed consent. The trial was conducted in accordance with the Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}